Australia's medicines regulator says its laws have failed to slow a growing number of people with blood toxicity attributed ...

State employee unions have been some of the most vocal critics of spending caps, and say they’ve led to dangerous ...

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.